We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Medical Cannabis Against Chronic Musculoskeletal Pain: a Mixed Methods Study.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05210660
Recruitment Status : Recruiting
First Posted : January 27, 2022
Last Update Posted : February 10, 2022
Sponsor:
Collaborators:
McGill University
Université de Sherbrooke
Information provided by (Responsible Party):
Dre Edeltraut Kröger, CHU de Quebec-Universite Laval

Brief Summary:
Despite many pharmaceutical options, there are no optimal treatments for Chronic musculoskeletal pain (CMP). Although many Canadians use medical cannabis (MC; legally authorized) to relieve their pain, there are no firm conclusions on the efficacy and safety of MC against CMP. In order to increase knowledge on this topic, it is essential to describe the current use of MC against CMP by Canadians and to understand patients' and physicians' perceptions and attitudes. Objectives: This study will evaluate the use of MC against CMP among adults and aims at: 1-Describing the use of MC in Canada, and the main characteristics of users and prescribers; 2-Identifying the therapeutic and adverse effects of MC from the users' perspective; 3a- Identifying the psychosocial, organizational, socio-demographic and health-related factors that influence the use and prescription of MC; and 3b- Quantifying the impacts of these factors on the use and prescription of MC in the management of CMP. Methods: 1) We will analyse available data on the users and prescribers of MC from Health Canada and from the Registre Cannabis Québec; 2) We will use mixed methods to collect data from patients affected by CMP and their physicians. Data from Health Canada will allow to document the prevalence and recent evolution of MC use. The qualitative phase of the second part of the study will identify obstacles and facilitators for the use AND for the prescribing of MC against CMP, including the need for more information in patients suffering from CMP and in physicians. Reasoned samples of patients and physicians will be recruited; information will then be collected by semi-structured interviews. For the quantitative phase, a pan-Canadian survey will be conducted, using a questionnaire built with the results of the qualitative phase of the study. The proposed study will describe the current use of MC against CMP in Canada and will allow to better understand the motivations and expectations of physicians and patients.

Condition or disease
Musculoskeletal Pain Cannabis Use

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Medical Cannabis Against Chronic Musculoskeletal Pain: a Mixed Methods Study to Describe Use and to Identify Its Facilitators and Barriers Among Canadian Patients and Doctors
Actual Study Start Date : January 21, 2020
Estimated Primary Completion Date : May 31, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana




Primary Outcome Measures :
  1. Use of any medical cannabis (MC) against chronic musculoskeletal pain (CMP) [ Time Frame: Use during the last month: cross sectional study ]
    Describe the current use of MC against CMP

  2. Authorization of any MC against CMP by a physician [ Time Frame: Use during the last month: cross sectional study ]
    Describe the current authorization of MC against CMP



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population

The study population for the qualititive part of the project is divided as follow:

30 patients, including at least 10 using medical cannabis, 15 physicians who follow patients with chronic musculoskeletal pain, including at least 5 physician who prescribe or have prescribed medical cannabis

Criteria

Inclusion Criteria patients (N=30):

  • 18 years old or older
  • Able to consent
  • Understand and speak French to be autonomous during the interview
  • Have chronic musculoskeletal pain (at least for the last 3 months)
  • OPTIONAL: have used medical cannabis against chronic musculoskeletal pain (for 10/30 recruited patients)

Inclusion Criteria physicians (N=15):

  • Hold a right to practice medicine in Canada
  • Practice medicine at the time of the research project
  • Understand and speak French to be autonomous during the interview
  • Follow patients with chronic musculoskeletal pain
  • OPTIONAL: Prescribe or have prescribed medical cannabis for chronic musculoskeletal pain (only for 5/15 recruited family physicians)

Exclusion Criteria:

There is no specific exclusion criteria. Participants who do not meet the inclusion criteria will be excluded from the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05210660


Contacts
Layout table for location contacts
Contact: Edeltraut Kröger, Ph.D. 418 682-7511 ext 84834 edeltraut.kroger.ciussscn@ssss.gouv.qc.ca

Locations
Layout table for location information
Canada
Hôpital du St-Sacrement Recruiting
Québec, Canada, G1S 4L8
Contact: Lise Poisblaud       lise.poisblaud@crchudequebec.ulaval.ca   
Sponsors and Collaborators
CHU de Quebec-Universite Laval
McGill University
Université de Sherbrooke
Investigators
Layout table for investigator information
Principal Investigator: Edeltraut Kröger, Ph.D. CHU de Québec-Université Laval
Layout table for additonal information
Responsible Party: Dre Edeltraut Kröger, Research Scientist, Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, CHU de Quebec-Universite Laval
ClinicalTrials.gov Identifier: NCT05210660    
Other Study ID Numbers: 411197
CU2-163003 ( Other Grant/Funding Number: Canadian Institutes of Health Research )
First Posted: January 27, 2022    Key Record Dates
Last Update Posted: February 10, 2022
Last Verified: February 2022
Keywords provided by Dre Edeltraut Kröger, CHU de Quebec-Universite Laval:
Medical cannabis
Musculoskeletal pain
Chronic pain
Non-cancer chronic pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Musculoskeletal Pain
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Muscular Diseases
Musculoskeletal Diseases
Pain
Neurologic Manifestations